#### A novel mutation in EROS (CYBC1) causes Chronic Granulomatous Disease 1

- Paige M Mortimer<sup>1\*</sup>, Esme Nichols<sup>1\*</sup>, Joe Thomas<sup>2\*</sup>, Rachna Shanbhag<sup>3</sup>, Neha 2
- Singh<sup>3</sup>, Eve L Coomber<sup>4</sup>, Talat H Malik<sup>1</sup>, Matthew C Pickering<sup>1</sup>, Lyra Randzavola<sup>1</sup>, 3
- William Rae<sup>5</sup>\$, Sagar Bhattad<sup>3</sup>\$, David C Thomas<sup>1</sup>\$ 4
- 5

#### Affiliations 6

- 7 <sup>1</sup>Centre for Inflammatory Disease, Department of Immunology and Inflammation,
- Imperial College London, United Kingdom 8
- 9 <sup>2</sup>Aster Medcity Hospital, Kochi, Kerala, India
- 10 <sup>3</sup>Aster CMI Hospital, Bangalore, India
- 11 <sup>4</sup> Wellcome Sanger Institute, Hinxton, United Kingdom
- 12 <sup>5</sup>Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R
- 13 and D, AstraZeneca, Cambridge, United Kingdom
- 14
- 15 \* joint first authorship
- 16 \$ joint senior authorship
- 17 Corresponding author: David. C. Thomas. Email: david.thomas1@imperial.ac.uk
- 18

#### 19 Key words

- 20 EROS
- 21 C170RF62
- 22 CYBC1
- 23 **Chronic Granulomatous Disease**
- 24 NOX2
- 25 gp91phox
- **Reactive Oxygen Species** 26
- 27
- 28 **Abbreviations**
- 29 ATT – Anti-Tuberculosis Treatment
- 30 CGD – Chronic Granulomatous Disease
- 31 DHR – Dihydrorhodamine
- EROS Essential for Reactive Oxygen Species 32
- 33 IEI – Inherited Error of Immunity
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. NADPH Nicotinamide adenine dinucleotide phosphate
- 34

#### 35 ROS – Reactive Oxygen Species

36

#### 37 Abstract

Chronic Granulomatous Disease (CGD) is an inborn error of immunity characterised 38 39 by opportunistic infection and sterile granulomatous inflammation. CGD is caused by a failure of reactive oxygen species (ROS) production by the phagocyte NADPH 40 41 oxidase. Mutations in the genes encoding phagocyte NADPH oxidase subunits cause CGD. We and others have described a novel form of CGD (CGD5) secondary to lack 42 43 of EROS (*CYBC1*), a highly selective chaperone for gp91*phox*. EROS-deficient cells 44 express minimal levels of gp91*phox* and its binding partner p22*phox*, but EROS also 45 controls the expression of other proteins such as P2X7. The full nature of CGD5 is currently unknown. We describe a homozygous frameshift mutation in CYBC1 leading 46 to CGD. Individuals who are heterozygous for this mutation are found in South Asian 47 populations (allele frequency = 0.00006545), thus it is not a private mutation. 48 49 Therefore, it is likely to be the underlying cause of other cases of CGD.

50

## 51 Keywords

52 EROS

- 53 CYBC1
- 54 Chronic granulomatous disease
- 55

## 56 Introduction

57 The multi-subunit phagocyte NADPH oxidase generates reactive oxygen species 58 (ROS) and is crucial for host defence <sup>1</sup>. Deficiencies in individual subunits (gp91*phox*, 59 p22phox, p47phox, p67phox and p40phox) of the phagocyte NADPH oxidase cause 60 chronic granulomatous disease (CGD), a severe inborn error of immunity (IEI) 61 characterised by severe infections with catalase positive organisms. Life threatening infections with Staphylococcus, Salmonella species, Burkholdheria and nocardia are 62 all well documented. Fungal infections with species such as Aspergillus are also 63 common and are associated with severe morbidity. While better anti-microbial 64 65 prophylaxis and treatment accompanied by the advent of bone marrow transplantation for CGD has improved outcomes, it remains a severe disease that requires prompt 66 identification and treatment. We previously showed that EROS/CYBC1 is essential for 67 the generation of ROS because it is the chaperone for the membrane-bound 68

69 gp91*phox*-p22*phox* heterodimer in both mouse and humans <sup>2–4</sup>. We and others have shown that mutations in EROS/CYBC1 can cause CGD5<sup>3,5</sup>. The small number of 70 71 cases described so far appear to have some typical features of CGD, such as opportunistic infections and inflammatory bowel disease, but also some features not 72 73 usually associated with CGD including; autoimmune haemolytic anaemia, chronic glomerulonephritis and even some viral infections. Thus far, the only pathogenic 74 EROS/CYBC1 mutations identified are private mutations restricted to one family <sup>3</sup> (as 75 a result of consanguineous marriage) or are limited to the Icelandic population <sup>5</sup>. We 76 77 describe a novel pathogenic mutation in EROS/CYBC1 that is likely to account for 78 more cases worldwide as awareness of CGD5 grows.

79

## 80 **Results/Case History**

A female in her twenties has been unwell for three years. Her childhood history is 81 notable for tuberculosis in the first five years of life and an episode of uveitis during 82 83 teenage years, which resolved following topical steroid treatment. She was otherwise 84 well. At the onset of symptoms she developed a prolonged cough and fever. She was 85 treated for radiographically proven pneumonia (Figure 1A) and responded to oral 86 antibiotics. However, she developed a dry cough and shortness of breath 3 months later. Two weeks into the illness, she developed a rash over the trunk, dry mouth and 87 88 swelling of her cervical lymph nodes. A biopsy of the skin rash showed erythema 89 annulare centrifugum and fine needle aspiration cytology of the neck nodes showed 90 granulomatous lesions. Testing by Mantoux and TB gold was negative. A CT scan of her chest showed upper zone nodules and ground glass opacities. ACE2 was elevated 91 92 at 122 (12-68 units/ml). With a working diagnosis of sarcoidosis she was started on 93 prednisolone (40 mg) and her respiratory symptoms, rash and neck nodes 94 resolved. The steroids were gradually tapered, and methotrexate was added but then 95 stopped due to liver dysfunction.

96

97 Between 4 and 7-months post-onset she was admitted to hospital three times for 98 episodes of dry cough and shortness of breath. She developed fever and chest pain 99 when steroids were reduced to 15 mg daily. A new CT chest showed traction 100 bronchiectasis, multiple peri-lymphatic and parenchymal nodules and a minimal right 101 pleural effusion. Bronchoalveolar lavage was negative for a TB panel, fungal stain and 102 culture. Given the complexity of her presentation, a PET CT was undertaken. It

103 showed a large necrotic lesion in the right lung with infiltration into the pleura (Figure 104 **1B**). A segmental resection of the involved lung by transthoracic surgery was carried 105 out. This demonstrated dematiaceous fungi (Malasezzia restricta). She was treated 106 with amphotericin B and steroids were continued. A blood culture at this time also 107 demonstrated methicillin resistant coagulase negative staphylococci. During this period, she had ongoing liver dysfunction and a liver biopsy showed granulomatous 108 109 hepatitis. She then developed fever and infection with Salmonella species was found 110 on blood culture. A bone marrow culture also reported Salmonella species. A bone 111 marrow biopsy showed granulomatous infiltration. In view of the granulomatous infiltration in multiple organs, anti-tubercular therapy (ATT) was started. She had 112 113 ongoing fevers in the next month, despite four weeks treatment with amphotericin and hence, amphotericin was stopped. Her dose of steroid was increased to 1mg/kg 114 115 prednisolone. With a combination of steroids and ATT, there was resolution of fever 116 and cough.

117

At 12 months from onset, the surgical wound caused by the lung biopsy failed to heal 118 119 and there was intermittent pus discharge from the wound. At this time, culture from 120 the wound showed growth of Mycobacterium tuberculosis (45-day culture) and 121 therapy was changed from modified ATT (in view of hepatitis and concurrent 122 Voriconazole treatment) to standard ATT (6 months modified ATT followed by 9 123 months standard ATT), following which the wound healed. However, on reducing 124 steroids there was recurrence of fever. Steroid sparing agents like mycophenolate 125 mofetil and azathioprine were trialled, with no response. She also developed 126 cushingoid features hence injected anti-TNF- $\alpha$  therapy (Adalimumab) was started 11 months post-onset, given for 6 months and stopped 16 months post-onset. 127 128 Corticosteroids were tapered and stopped 15 months post-onset. She had a recurrence of fever at 17 months from onset and was treated with steroids and 2 doses 129 130 of injected rituximab for a presumed flare of an autoinflammatory manifestation. At 19 131 months post-onset she developed fever and severe cough with hypoxia requiring ventilation. She was treated for atypical stenotrophomonas maltophila pneumonia with 132 133 antibiotics, anti-fungals and intravenous immunoglobulin. She remained well for the 134 next year on steroids, azathioprine and hydroxychloroquine. At 31 months post-onset 135 she developed recurrence of fever and cough. A CT scan of the chest showed right

7th rib osteomyelitis near the previous surgical wound (Figure 1C). A rib excision was
carried out that again showed dematiaceous fungi (Cladophialophora spp, Figure
1D) and she was treated with itraconazole for 1.5 months. A summary of her clinical
course is shown in Figure 1E.

140

Given her unusual presentation with multiple episodes of severe infection and inflammation, she underwent whole exome sequencing. This demonstrated a homozygous mutation in the *CYBC1* gene (rs1291759701), Exon 7, c.327dup (p.Val110CysfsTer40), predicted to be pathogenic and a provisional diagnosis of diagnosis of CGD was established. This was confirmed by Sanger sequencing (**Figure** 146 **2A**). There were no deleterious mutations in known NADPH oxidase subunits.

147 This mutation results in the insertion of a nucleotide that has two linked consequences:

- 148 (i) A frameshift from amino acid 110
- 149 (ii) A premature stop codon at amino acid 140

Gnomad curates this variant as a putative loss-of-function variant <sup>6</sup>. There are no homozygotes for this allele (or for any other EROS/*CYBC1* loss of function allele) in Gnomad, although heterozygotes are reported at a minor allele frequency of 0.00006545 in South Asian populations. The variant was not noted in any other ethnic group <sup>6</sup>.

155

156 We performed experiments to examine whether this mutation was pathogenic. First, we used site directed mutagenesis to recapitulate the c.327dup (p.Val110CysfsTer40) 157 158 mutation found in the patient in a pcDNA3.1 vector that expresses untagged EROS. 159 We transfected the control and mutant vectors into HEK293 cells. In line with our 160 previous studies, transfection with the control vector led to high levels of EROS 161 expression <sup>4</sup>. However, expression of the mutant vector did not lead to expression of 162 any detectable EROS protein in multiple experiments and in a variety of transfection conditions (Figure 2B). The lack of expression of EROS protein by the mutant allele 163 164 was not due to a failure of RNA expression or differing transfection efficiency; RNA expression of EROS at multiple exon junctions was equivalent following transfection 165 166 of both control and mutant alleles (Figure 2C). We also saw no expression of the mutant allele compared with the wild-type allele when transfected into NIH3T3 cells, 167

168 which express no endogenous EROS protein (supplementary figure 1A). We reasoned that some mutant frameshifted EROS protein might still be made from the 169 170 mutant allele but that it is no longer recognised by the anti-EROS antibody, which is 171 specific for the C-terminus of the protein. To address this, we also engineered the 172 mutant into a vector in which human EROS is fused with GFP at its C-terminus by site directed mutagenesis. Using GFP as a proxy for EROS expression we observed 173 174 strong expression of the control vector but negligible expression of the mutant (Figure 175 2D). Similar results were also seen when we electroporated control and mutant GFP 176 vectors into EROS deficient clone 14 cells (supplementary figure 1B).

Our previous work demonstrates the importance of EROS on gp91*phox* stability <sup>4</sup>. Cotransfection of gp91*phox* with EROS leads to much greater expression of gp91*phox*than transfection of the gp91*phox* construct alone. Expression of the immature 58kDa
gp91*phox* precursor was markedly increased by wild type EROS but not by the mutant
vector (Figure 2E).

A further way to assess whether a mutation in EROS leads to a functional effect is to use an EROS-GFP expressing lentivirus to reconstitute EROS expression in our previously described EROS-deficient PLB985 cell line, and determine whether this restores gp91*phox* expression (**supplementary figure 1B**). We created the c.327dup (p.Val110CysfsTer40) mutation in our lentiviral vector. As expected, this also led to negligible EROS protein expression and no reconstitution of gp91*phox* expression (**Figure 2F-H**).

189

# 190 Discussion

191 CGD is a life threatening inborn error of immunity associated with severe morbidity 192 and premature mortality. Early diagnosis is important as the prognosis is improved by 193 factors such as appropriate prophylactic therapy, prompt treatment of severe fungal 194 infections, recognition of inflammatory complications and management at specialist centres. Similarly, recent experience with haematopoietic stem cell therapy suggests 195 196 that outcomes are excellent if patients are transplanted before they accrue severe 197 complications in CGD, though more data are still required <sup>7,8</sup>. Until recently, much of 198 our knowledge of CGD was based on experience in high income countries such as 199 the USA<sup>9</sup>, Western Europe<sup>10</sup> and Japan<sup>11</sup>. Recently, there have been descriptions of cohorts in lower/middle income countries and these highlight distinct features of CGD 200 201 such as the predominance of autosomal recessive CGD over X-linked CGD<sup>12,13</sup>.

Mutations in EROS/*CYBC1* remain scarce and it is difficult to determine at present to what extent this form of IEI resembles classical CGD caused by mutations in gp91*phox*, p22*phox*, p47*phox* and p67*phox*. Notably, p40*phox* deficiency is a distinct clinical entity from those described above <sup>14,15</sup>. Two major factors suggest that EROS/*CYBC1* deficiency may have distinct features:

- 207 (i) EROS deficiency removes most but not all gp91*phox*-p22*phox*
- 208

(ii)

EROS controls the expression of other proteins such as P2X7 <sup>2,4,16</sup>.

209 The patient we describe has a clinical history compatible with CGD including repeated 210 episodes of granulomatous inflammation, severe and repeated infection with both 211 bacterial and fungal pathogens and autoinflammatory phenomena. Septicaemia from Salmonella species is well recognised in CGD <sup>10,17,18</sup>. Severe susceptibility to 212 Salmonella Typhimurum infection in an in vivo screen was the means by which EROS 213 214 was discovered <sup>2</sup>. Osteomyelitis due to Cladophialophora has also been described in 215 CGD <sup>19</sup>. Mycobacterial infections are well recognised in CGD, particularly in areas of the world where they are endemic <sup>20</sup>. 216

217 CGD is increasingly recognised in India. A previous report from a large centre in India 218 showed that while they had described 17 cases before 2013, they described a further 219 21 between 2013 and 2017<sup>21</sup>. A recent multi-centre study of 236 patients in India expanded the phenotype further <sup>22</sup>. This cohort focused largely on patients with 220 221 mutations in CYBB (gp91phox) and NCF1 (p47phox). In many respects, the patient 222 that we describe here had a typical course for "classic" CGD both in terms of the 223 localisation of infection and the organisms identified. For instance, she had pneumonia 224 and lung inflammation, lymphadenitis, liver abscess and septicaemia. These are all well recognised features of CGD in general and also in the recent Indian cohort study. 225 226 Similarly, the organisms identified in this patient are also well recognised CGD 227 pathogens.

Our study is limited by the lack of availability of patient cells to confirm the absence of EROS, gp91*phox* and p22*phox* protein expression secondary to the mutation. This was caused by the logistical difficulties of transporting blood from the remote area in which the patient lived. Nevertheless, we were able to confirm the mutation by Sanger sequencing and demonstrate that it led to no detectable protein expression in several

cell lines. These data, together with the typical clinical course, make it overwhelmingly
likely that this is the third described mutation in EROS/CYBC1 deficiency (CGD5).

Individuals that are heterozygous for the mutation we describe here have been observed in databases such as Gnomad, thus far restricted to people of South Asian ancestry. As such, we predict that there will be more cases of CGD5 caused by this mutation in EROS/*CYBC1*, both in India and elsewhere. The diagnosis should be considered in cases of CGD or other inborn errors of immunity, particularly when the generation of ROS is impaired without mutations in *CYBB, CYBA, NCF1, NCF2* and *NCF4*.

#### 242 Methods

#### 243 <u>Consent</u>

Informed consent for this study was obtained from the patient and family and ethical
approval was granted by the Institutional Ethics Committee of Aster CMI Hospital,
Bengaluru. IEC Regd. No. ECR/1084/Inst/KA/2018. The patient and their family are
happy for the case to be published.

#### 248 <u>Cell line culture</u>

HEK293 and HEK293T cells were grown in complete DMEM (DMEM (Gibco) + 10%
FBS (Pan biotech) + 1% penicillin-streptomycin-glutamine (ThermoFisher) + 1%
sodium pyruvate (ThermoFisher). PLB985 and EROS-/- PLB985 cell lines were grown
in complete RPMI (RPMI 1640 (Gibco), + 10% FBS + 1% penicillin-streptomycinglutamine + 1% sodium pyruvate + 1% HEPES (ThermoFisher) +1% GlutaMAX
(ThermoFisher)).

#### 255 DNA plasmids

DNA plasmids were obtained from Origene; untagged human EROS (SC324452),
GFP tagged human EROS (RG200883) untagged gp91*phox* (SC122091), lentiEROS
GFP tagged (RC200883L4) and equivalent empty vector (PS100093).

## 259 Sanger sequencing

Patient and healthy donor DNA was isolated from whole blood using the Gentra
PureGene kit (Qiagen), according to manufacturers' instructions. DNA was subjected

262 to standard PCR with the primers listed below. Amplified DNA was sequenced by

- 263 GeneWiz and aligned using SnapGene.
- 264 Forward: AGTGCAGTGTAAAGATGG
- 265 Reverse: GTCCACAAACTCATCTCC
- 266 Site-directed mutagenesis
- 267 A vector encoding EROS was generated using site-directed mutagenesis with primers
- 268 listed below. Transfection was performed using QuikChange Lightning Multi Site-
- 269 Directed Mutagenesis Kit (Agilent) as per the manufacturer's instructions.
- 270 Forward (F327T): TGCTCCATGATGTCCGTGATTGTGAGCGTGGA
- 271 Reverse (R327A): TCCACGCTCACAATCACGGACATCATGGAGCA

## 272 Transfection

- 273 HEK293/T cells were transfected with 1.2-1.8ng of DNA using lipofectamine RNAiMAX
- 274 (Invitrogen) or lipofectamine2000 (Invitrogen). Cells were harvested at 48 or 72hrs for
- 275 RNA, protein extraction and flow cytometry analysis.

## 276 <u>Nucleofection</u>

EROS-/- PLB985 cells were nucleofected using the SF cell line 4D-Nucleofector X Kit
L (Lonza), following manufacturer's instructions. 1.2ng EROS-GFP or mutant EROSGFP DNA was pulsed into cells using the EN-138 programme. Cells were harvested
after 48hrs for flow cytometry analysis.

## 281 Western blot

1x10<sup>6</sup> cells were lysed with Pierce RIPA lysis buffer (ThermoFisher) containing 1x 282 283 protein phosphatase inhibitor (ThermoFisher) and incubated for 30 minutes on ice. 284 Debris was pelleted by centrifugation at 14000xg for 30 minutes at 4°C. Protein 285 concentration was determined by BCA assay (ThermoFisher) according to 286 manufacturer's instructions. 20µg of protein was mixed with 4x LDS sample buffer 287 (ThermoFisher) + 10% reducing agent (Invitrogen) and denatured at 72°C for 10 288 minutes. Samples were run on NuPAGE 4-12% Bis-Tris gels (ThermoFisher) in 1x MOPS running buffer (Formedium) at 100-150v for 60-90mins. Proteins were 289

290 transferred to a nitrocellulose membrane (ThermoFisher) in transfer buffer (3.05g Tris 291 base (Sigma) + 14.45g Glycine (Sigma) + 800ml dH2O + 200ml methanol) and ran for 292 1 hour 15 mins at 100v. The membrane was blocked in 5% skim milk (Marvel) in TBST 293 for 1 hour at room temperature. Membrane was cut and probed with appropriate 294 primary antibody; actin (1:2500, abcam), EROS (1:1000, Atlas), gp91phox (1:1000, 295 Santa Cruz), vinculin (1:1000, CST) in blocking buffer overnight at 4°C on a roller. 296 Membranes were washed 3x in TBST for 10 minutes and incubated with appropriate 297 secondary antibody (anti-rabbit IgG horseradish peroxidase, 1:10000 (CST) or anti-298 mouse IgG horseradish peroxidase, 1:10000 (CST)) in blocking buffer for 1 hour at 299 room temperature. The blots were developed with SuperSignal West Pico PLUS (ThermoFisher) or SuperSignal West Femto PLUS (ThermoFisher) according to 300 301 manufacturer's instructions and imaged on a ChemiDoc (BioRad).

## 302 <u>qPCR</u>

303  $1 \times 10^{6}$  cells were resuspended in RLT buffer (QIAGEN) + 10%  $\beta$ -mercaptoethanol 304 (Sigma) on ice. RNA was extracted using QIAGEN RNAeasy mini kit according to 305 manufacturer's instructions. cDNA synthesis was carried out using superscript IV VILO master mix (Invitrogen) according to manufacturer's instructions using 1µg of RNA. 306 307 gPCR performed using TagMan Fast advanced master mix (ThermoFisher) according 308 to manufacturer's instructions. EROS primers used were Hs00978805 exon 2-3, 309 Hs00978806 exon 3-4, Hs00978808 exon 5-6 and housekeeping HPRT Hs02800695 310 (ThermoFisher).

## 311 Flow cytometry

312 GFP tagged samples were acquired on a LSRFortessa (BD).

## 313 Generation of lentivirus

Lentiviral mix was added to HEK293T cells at a ratio of 4 lentiviral plasmid: 3 psPAX2 (Addgene): 1 pMD2.G (Addgene), using 7µg of lentiviral plasmid in lipofectamine2000. Cells were incubated at 37°C, 5% CO<sub>2</sub> for 48hrs. The viral supernatant was harvested and filtered and concentrated using LentiX concentrator (Takara). Transfected HEK293T cells were harvested and analysed by flow cytometry to assess transfection efficiency.

# 320 Lentiviral transduction

- 321 1x10<sup>5</sup> PLB985 and EROS-/- PLB985 cells were transduced with viral supernatant plus
- 322 8µg/ml polybrene (Merck) and incubated at 37°C, 5% CO2 for 72 hrs. Transduction
- 323 efficiency was analysed by flow cytometry to determine GFP expression. Remaining
- 324 cells were expanded in culture and harvested for western blot.
- 325 Figures were created using Biorender.
- 326

# 327 Funding Statement

- 328 This work was supported by funding from a Wellcome-Beit Prize Trust Clinical
- 329 Research Career Development Fellowship (20661206617/A/17/Z and 206617/A/17/A)
- and the Sidharth Burman endowment. MCP is a Wellcome Trust Senior Fellow in
- 331 Clinical Science (212252/Z/18/Z) and THM is supported by this fellowship.
- 332

We acknowledge support from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare National Health Service Trust and Imperial College London, and from the NIHR Clinical Research Network. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIH, or the Department of Health.

338

We thank the LMS/NIHR Imperial Biomedical Research Centre Flow CytometryFacility for their support.

- 341
- 342
- 343



- 346 (A) Chest x-ray of pneumonia. (B) PET CT scan of a large necrotic lesion in the right
- 347 lung with infiltration into the pleura. **(C)** CT scan of right 7th rib osteomyelitis near
- 348 previous surgical wound. (D) Dematiaceous fungi growth from excised rib. (E)
- 349 Timeline of the patient's clinical course.



# 352 **Figure 2: Novel EROS mutation abrogates EROS and cannot support**

# 353 gp91phox expression

- 354 (A) Sanger sequencing of CYBC1 in patient carrying the c.327dup
- 355 (p.Val110CysfsTer40) mutation. (B) Normal and c.327dup (p.Val110CysfsTer40)
- 356 EROS DNA was transfected into HEK293 cells and EROS protein expression
- 357 measured by western blot and (C) gene expression measured by qPCR. EROS
- 358 probes targeting several exon junctions were used. EROS is shown relative to
- 359 HRPT. (D) GFP-tagged c.327dup (p.Val110CysfsTer40) and normal EROS DNA
- 360 were transfected into HEK293 cells and analysed by flow cytometry. (E) Normal or
- 361 c.327dup (p.Val110CysfsTer40) EROS was co-transfected with gp91phox into
- 362 HEK293 cells and analysed by western blot. (F) Normal or GFP-tagged c.327dup
- 363 (p.Val110CysfsTer40) EROS DNA were cloned into a lentiviral backbone,
- 364 transfected into HEK293T cells and transfection efficiency evaluated by flow
- 365 cytometry. (G) The resulting lentivirus was used to transduce normal or GFP-tagged
- 366 c.327dup (p.Val110CysfsTer40) EROS DNA into PLB985 EROS-/- cells, GFP
- 367 expression was measured by flow cytometry and **(H)** expression of gp91*phox* and
- 368 EROS was determined by western blot. Data are representative of n=3 experiments.
- 369 N.S = non-specific band.
- 370



#### 371 372

## 373 Supplemental Figure 1:

374 (A) Normal and c.327dup (p.Val110CysfsTer40) EROS DNA was transfected into

375 NIH3T3 cells and EROS and gp91*phox* protein expression was measured by

376 western blot **(B)** GFP-tagged c.327dup (p.Val110CysfsTer40) and normal EROS

377 DNA were nucleofected into PLB985 EROS-/- cells. (C) Transduction of normal

378 EROS successfully reconstituted gp91*phox* expression in PLB985 EROS-/- cells.

379 Actin or vinculin used as loading control. Data are representative of n=3

380 experiments.

381

## 382 Acknowledgements

- 383 We thank the patient and family for their contributions to this research. We thank Dr
- 384 Kerry Rostron for facilitating several logistic aspects of this study.
- 385

# 386 **Declarations**

387 None of the authors has any potential financial conflict of interest related to this
 388 manuscript. Declarations of interest: none - manuscript file

389

# 390 **References**

- 391 1 Mortimer PM, Mc Intyre SA, Thomas DC. Beyond the Extra Respiration of
- 392 Phagocytosis: NADPH Oxidase 2 in Adaptive Immunity and Inflammation.
- 393 *Front Immunol* 2021; **12**. DOI:10.3389/fimmu.2021.733918.
- Thomas DC, Clare S, Sowerby JM, *et al.* Eros is a novel transmembrane
   protein that controls the phagocyte respiratory burst and is essential for innate
   immunity. *Journal of Experimental Medicine* 2017; **214**: 1111–28.
- 397 3 Thomas DC, Charbonnier L-M, Schejtman A, *et al.* EROS/CYBC1 mutations:
   398 Decreased NADPH oxidase function and chronic granulomatous disease.
   399 *Journal of Allergy and Clinical Immunology* 2019; **143**: 782-785.e1.
- 400 4 Randzavola LO, Mortimer PM, Garside E, *et al.* EROS-mediated control of
- 401 NOX2 and P2X7 biosynthesis. 2021. DOI:10.1101/2021.09.14.460103.
- 402 5 Arnadottir GA, Norddahl GL, Gudmundsdottir S, *et al.* A homozygous loss-of403 function mutation leading to CYBC1 deficiency causes chronic granulomatous
  404 disease. *Nat Commun* 2018; **9**. DOI:10.1038/s41467-018-06964-x.
- 405 6 Karczewski KJ, Francioli LC, Tiao G, *et al.* The mutational constraint spectrum
  406 quantified from variation in 141,456 humans. *Nature 2020 581:7809* 2020;
  407 **581**: 434–43.
- Chiesa R, Wang J, Blok HJ, *et al.* Hematopoietic cell transplantation in chronic
  granulomatous disease: a study of 712 children and adults. *Blood* 2020; **136**:
  1201–11.
- 411 8 Morris EC. HCT for CGD? Yes, and the sooner the better. *Blood* 2020; **136**:
  412 1121–3.
- 413 9 Leiding JW, Holland SM. Chronic Granulomatous Disease. *GeneReviews*®
  414 2022; published online April 21.
- 415 https://www.ncbi.nlm.nih.gov/books/NBK99496/ (accessed Nov 11, 2022).

416 10 van den Berg JM, van Koppen E, Åhlin A, *et al.* Chronic Granulomatous

417 Disease: The European Experience. *PLoS One* 2009; **4**.

418 DOI:10.1371/JOURNAL.PONE.0005234.

- 419 11 Yanagimachi M, Kato K, Iguchi A, *et al.* Hematopoietic Cell Transplantation for
  420 Chronic Granulomatous Disease in Japan. *Front Immunol* 2020; **11**: 1617.
- 421 12 Mortaz E, Azempour E, Mansouri D, et al. Common Infections and Target
- 422 Organs Associated with Chronic Granulomatous Disease in Iran. *Int Arch*423 Allergy Immunol 2019; **179**: 62–73.
- 424 13 Bakri FG, Mollin M, Beaumel S, *et al.* Second Report of Chronic
- 425 Granulomatous Disease in Jordan: Clinical and Genetic Description of 31
- 426 Patients From 21 Different Families, Including Families From Lybia and Iraq.

427 *Front Immunol* 2021; **12**: 639226.

- Matute JD, Arias AA, Wright NAM, *et al.* A new genetic subgroup of chronic
  granulomatous disease with autosomal recessive mutations in p40phox and
  selective defects in neutrophil NADPH oxidase activity. *Blood* 2009; **114**: 3309.
- 431 15 van de Geer A, Nieto-Patlán A, Kuhns DB, *et al.* Inherited p40phox deficiency
  432 differs from classic chronic granulomatous disease. *J Clin Invest* 2018; **128**:
  433 3957.
- 434 16 Ryoden Y, Fujii T, Segawa K, Nagata S. Functional Expression of the P2X7
- 435 ATP Receptor Requires Eros. *The Journal of Immunology* 2020; **204**: 559–68.
- 436 17 Lin TS, Lee JH, Wang LC, *et al.* Clinical features and outcomes of patients
- 437 with chronic granulomatous disease in Taiwan. *Journal of Microbiology,*
- 438 *Immunology and Infection* 2022; published online July 6.
- 439 DOI:10.1016/J.JMII.2022.06.005.
- 440 18 Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease.
  441 *Clin Exp Immunol* 2014; **175**: 139.
- Shigemura T, Agematsu K, Yamazaki T, *et al.* Femoral osteomyelitis due to
  Cladophialophora arxii in a patient with chronic granulomatous disease. *Infection 2009 37:5 2009*; **37**: 469–73.
- Conti F, Lugo-Reyes SO, Blancas Galicia L, *et al.* Mycobacterial disease in
  patients with chronic granulomatous disease: A retrospective analysis of 71
  cases. *Journal of Allergy and Clinical Immunology* 2016; **138**: 241-248.e3.

- 448 21 Rawat A, Vignesh P, Sharma A, et al. Infection Profile in Chronic
- 449 Granulomatous Disease: a 23-Year Experience from a Tertiary Care Center in
- 450 North India. *J Clin Immunol* 2017; **37**: 319–28.
- 451 22 Rawat A, Vignesh P, Sudhakar M, et al. Clinical, Immunological, and Molecular
- 452 Profile of Chronic Granulomatous Disease: A Multi-Centric Study of 236
- 453 Patients From India. *Front Immunol* 2021; **12**.
- 454 DOI:10.3389/fimmu.2021.625320.
- 455